ArticleBMC psychiatry2019
Antidepressant prescription practice and related factors in Switzerland: a cross-sectional analysis of health claims data.
Article in BMC psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Antidepressant prescribing patterns and patient-reported adverse effects: a cross-sectional study from Pakistan.Annals of general psychiatry · 2026Article
- Antidepressant drug switching in the Swiss population with a focus on Escitalopram and drugs with pharmacogenetic dosing guidelines: a drug utilization study using claims data.The pharmacogenomics journal · 2025Article
- Utilization of clinical practice guidelines and interprofessional collaboration in depression management in Swiss primary care: a cross-sectional survey study among primary care physicians.BMC primary care · 2025Article
- Discrepancy between antibiotic pack sizes and guideline recommendations: a real-world analysis based on claims data.Infection · 2025Observational
- Delirium in Neurocritical Care: Uncovering Undisclosed Psychotropic Substance and Medication Use and Stress Exposure by Hair Analysis.Neurocritical care · 2025Article
- Article
- Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Prevalence, trends, and individual patterns of long-term antidepressant medication use in the adult Swiss general population.European journal of clinical pharmacology · 2023Article
- Agricultural activities and risk of treatment for depressive disorders among the entire French agricultural workforce: the TRACTOR project, a nationwide retrospective cohort study.The Lancet regional health. Europe · 2023Article
- Opioid prescriptions after knee replacement: a retrospective study of pathways and prognostic factors in the Swiss healthcare setting.BMJ open · 2023Article
- Patterns of patients with polypharmacy in adult population from Korea.Scientific reports · 2022Article
- Healthcare use for major depressive disorders among middle-aged and older adults in the community.Social psychiatry and psychiatric epidemiology · 2022Article
- Does hospital volume affect outcomes after abdominal cancer surgery: an analysis of Swiss health insurance claims data.BMC health services research · 2022Article
- Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2022Article
- Did the introduction and increased prescribing of antidepressants lead to changes in long-term trends of suicide rates?European journal of public health · 2021Article
- Article
- Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum.Therapeutic advances in psychopharmacology · 2020Article
- Trends in Micronutrient Laboratory Testing in Switzerland: A 7-Year Retrospective Analysis of Healthcare Claims Data.International journal of general medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the study was to examine the prevalence of and factors associated with antidepressant (AD) prescriptions in order to draw a comprehensive picture of prescribing practices in Switzerland.
methodWe conducted a population-based, cross-sectional descriptive study using a large Swiss healthcare claims database, covering approximately 13% of the Swiss population. AD prescription was determined by identifying patients (N = 105,663) with health claims data of at least 1 AD prescription in the year 2016. AD medication was identified using ATC-codes classified by the World Health Organisation. Univariate, bivariate and multivariate analyses using logistic regression were performed.
resultsThe extrapolated 1-year prevalence of AD prescription was 8.7% (95% CI, 8.7-8.8) with two thirds of AD recipients being female and the average age being 59 years (SD = 19.1). The regional distribution of prescription rates varied between cantons and ranged from 6.5 to 11.7%. Logistic regression revealed higher prescription rates among females compared to males (OR: 1.52) and an increased probability of AD prescription by age up until 54 years (OR: 2.25) and ≥ 85 years (OR: 2.32). Comorbidity is associated with higher odds (OR: 3.26 with 1-2 comorbidities) and enrollment in a managed care plan (compared to standard care) with lower odds for an AD prescription (OR: 0.85).
conclusionThis study is the first in Switzerland to describe the prevalence of and factors associated with AD prescription based on a large health claims database reflecting routine care. The results provide important information about regional variation, prescription source, and potential over-prescription in the treatment of depressive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.